P18 Adjusted Comparison of Teclistamab Versus Real-World Physician’s Choice (RWPC) of Therapy in Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
Abstract
Authors
M.V. Mateos A. Chari S.Z. Usmani H. Goldschmidt K. Weisel K. Qi A. Londhe S. Nair X. Lin L. Pei E. Ammann K. Chastain T. Parekh A. Marshall M. Slavcev P. Moreau